Antiphospholipid syndrome (APS), also known as Hughes syndrome, is a rare acquired autoimmune disorder caused by persistent autoantibodies directed against phospholipid-binding proteins, creating a hypercoagulable state. Per Orphanet (Orphanet:80) and GARD (GARD:5824), the resulting abnormal clotting tendency can produce blood clots, stroke, heart attack, and significant pregnancy-related complications including miscarriage and stillbirth. APS is classified into four subtypes: primary antiphospholipid syndrome (occurring independently), secondary APS (occurring alongside other autoimmune disorders, most commonly lupus erythematosus), catastrophic antiphospholipid syndrome (CAPS — a rare, severe variant), and familial antiphospholipid syndrome. The condition is also associated with infectious diseases including syphilis and Lyme disease. APS is not a genetic disorder in the traditional inherited sense; it arises from immune dysregulation.

APS produces vascular, obstetric, neurological, and dermatologic manifestations. Per Orphanet phenotype data, arterial thrombosis and venous thrombosis each occur in 30–79% of affected individuals. Ischemic stroke and transient ischemic attack are frequent neurological events, each reported in 30–79% of cases. Obstetric involvement is prominent: intrauterine growth retardation is documented in 80–99% of affected pregnancies, premature birth and female infertility each in 30–79%. Hypertension occurs in 30–79% of cases. Characteristic dermatologic findings include livedo reticularis and livedo racemosa, both in the 30–79% frequency range. Antiphospholipid antibody positivity — including anticardiolipin IgG, anticardiolipin IgM, anti-beta-2 glycoprotein I IgG, anti-beta-2 glycoprotein I IgM, and lupus anticoagulant — is a defining laboratory feature in 30–79% of cases. Hypercoagulability is a frequent systemic finding. Fatigue and pain are common. Occasional manifestations include gangrene and additional antiphospholipid antibody specificities (anti-phosphatidyl inositol, anti-phosphatidyl serine, anti-phosphatidyl glycerol, anti-annexin-V).

APS is an acquired autoimmune condition. Autoantibodies against phospholipid-binding proteins promote platelet activation and dysregulation of the coagulation cascade, producing the characteristic thrombotic and obstetric phenotype. The packet does not document specific genetic risk loci. Familial clustering is recognized — the familial APS subtype is documented — but a specific inheritance pattern is not described in this packet. Secondary APS arises in the context of other autoimmune disorders, particularly systemic lupus erythematosus, as well as certain infections. The packet does not document known causative genes, consistent with the acquired autoimmune etiology.

Diagnosis integrates clinical findings with laboratory confirmation. The characteristic laboratory abnormalities — positive antiphospholipid antibodies including anticardiolipin, anti-beta-2 glycoprotein I, and lupus anticoagulant — are documented in this packet as frequent phenotypic findings (30–79%). Clinical criteria involve documented thrombotic events or pregnancy morbidity. A long-term genetic risk factor registry study (NCT00482794, Duke University, ongoing since 2006) is investigating heritable contributors to antiphospholipid antibody syndrome. The packet does not specify formal classification criteria versions (such as Sapporo or revised Sapporo criteria), testing intervals, or required antibody positivity duration.

No FDA-approved treatments with active market status are documented in this packet for antiphospholipid syndrome. The orphan drug data in this packet contains a record for pentadecanoic acid designated for a different condition (PIGW-CDG) — this does not represent a treatment relevant to APS and is not included in this summary. Investigational agents are under evaluation in active clinical trials, including a Phase 2 trial of anifrolumab (NCT07584083) and Phase 1 studies of RAY121 (NCT06371417) and EA5 injection (NCT07632976). Standard anticoagulation approaches used in APS clinical care are not detailed in this packet.

Natural history and long-term prognosis information are not documented in this packet. The clinical course is shaped by thrombotic burden, obstetric outcomes, and the presence of associated autoimmune conditions; however, formal prognosis data are absent from this packet.

Per ClinicalTrials.gov, 50 active trials are registered for antiphospholipid syndrome. Ongoing studies include a Phase 2 trial of anifrolumab in primary APS (AnifAPS Trial, NCT07584083, National and Kapodistrian University of Athens, recruiting through 2028), a Phase 1 dose-escalation study of RAY121 in immunological diseases including APS (RAINBOW Trial, NCT06371417, Chugai Pharmaceutical, recruiting), and a Phase 1 study of EA5 injection for APS with recurrent thrombosis (NCT07632976, Shanghai Lanyi Therapeutics). An international registry of thrombotic APS patients treated with direct oral anticoagulants is actively enrolling (NCT04262492, ongoing through 2031). A multicenter cohort study of thrombocytopenia trajectories in APS is recruiting (NCT07757789). A study of autoreactive B lymphocytes in autoimmune diseases including APS is enrolling through 2031 (NCT07251179, University Hospital Strasbourg). Published research totals 209 classified publications, dominated by reviews and meta-analyses (73 of 209), with active biomarker and clinical trial publication streams. Authoritative resources include Orphanet (Orphanet:80) and the NIH GARD database (GARD:5824).